Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
Rationale: Less invasive, nonsurgical approaches are needed to treat severe emphysema. Objectives: To evaluate the effectiveness and safety of the Spiration Valve System (SVS) versus optimal medical management. Methods: In this multicenter, open-label, randomized, controlled trial, subjects aged 40 years or older with severe, heterogeneous emphysema were randomized 2:1 to SVS with medical management (treatment) or medical management alone (control). Measurements and Main Results: The primary efficacy outcome was the difference in mean FEV1 from baseline to 6 months. Secondary effectiveness outcomes included: difference in FEV1 responder rates, target lobe volume reduction, hyperinflation, health status, dyspnea, and exercise capacity. The primary safety outcome was the incidence of composite thoracic serious adverse events. All analyses were conducted by determining the 95% Bayesian credible intervals (BCIs) for the difference between treatment and control arms. Between October 2013 and May 2017, 172 participants (53.5% male; mean age, 67.4 yr) were randomized to treatment (n = 113) or control (n = 59). Mean FEV1 showed statistically significant improvements between the treatment and control groups—between-group difference at 6 and 12 months, respectively, of 0.101 L (95% BCI, 0.060–0.141) and 0.099 L (95% BCI, 0.048–0.151). At 6 months, the treatment group had statistically significant improvements in all secondary endpoints except 6-minute-walk distance. Composite thoracic serious adverse event incidence through 6 months was greater in the treatment group (31.0% vs. 11.9%), primarily due to a 12.4% incidence of serious pneumothorax. Conclusions: In patients with severe heterogeneous emphysema, the SVS shows significant improvement in multiple efficacy outcomes, with an acceptable safety profile. Clinical trial registered with www.clinicaltrials.gov (NCT01812447).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [181]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Endoscopic or surgical lung volume reduction (LVR), an important treatment option for patients with COPD, can improve lung function and quality of life and has demonstrated survival benefits in selected patients [44].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071 · cited 1×
“9–12% documented in randomized LVRS trials (7).”
Qaseem, A., Wilt, T. J., Weinberger, S. E., Hanania, N. A., Criner, G., van der Molen, T., Marciniuk, D. D., Denberg, T., Schünemann, H., Wedzicha, W., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-3-201108020-00008 · Cited by 1,087
Self-citationKeating, A., Lee, A., & Holland, A. E. (2011) · Chronic Respiratory Disease · doi:10.1177/1479972310393756 · Cited by 583 · cited 1×
“The EMPROVE study was designed with the understanding that only z40% of patients with COPD actually adhere to a PR program due to problems with access and prohibitive cost (27).”
MethodCooper, J. D., Patterson, G. A., Sundaresan, R. S., Trulock, E. P., Yusen, R. D., Pohl, M. S., & Lefrak, S. S. (1996) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(96)70147-2 · Cited by 518
Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation
Klooster, K., ten Hacken, N. H. T., Hartman, J. E., Kerstjens, H. A. M., van Rikxoort, E. M., & Slebos, D.-J. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507807 · Cited by 487 · cited 4×
“However, pneumothorax was the only individual SAEs with significantly higher treatment group incidence, similar to comparable studies (13, 25).”
BackgroundResultInfluentialCriner, G. J., Sue, R., Wright, S., Dransfield, M., Rivas-Perez, H., Wiese, T., Sciurba, F. C., Shah, P. L., Wahidi, M. M., de Oliveira, H. G., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201803-0590oc · Cited by 428 · cited 6×
“This improvement is not surprising, as LIBERATE patients were required to maintain a supervised PR program throughout study follow-up (25), and PR has been shown to improve exercise capacity in patients with COPD (26).”
BackgroundResultInfluentialSelf-citationQaseem, A., Snow, V., Shekelle, P., Sherif, K., Wilt, T. J., Weinberger, S., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians* (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00008 · Cited by 424
Kemp, S. V., Slebos, D.-J., Kirk, A., Kornaszewska, M., Carron, K., Ek, L., Broman, G., Hillerdal, G., Mal, H., Pison, C., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201707-1327oc · Cited by 390 · cited 3×
“These efficacy results are very comparable to other randomized clinical trials using one-way valves in a unilateral lobar treatment paradigm (13, 14, 16, 25).”
BackgroundResultEndobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study
Valipour, A., Slebos, D.-J., Herth, F., Darwiche, K., Wagner, M., Ficker, J. H., Petermann, C., Hubner, R.-H., Stanzel, F., & Eberhardt, R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1383oc · Cited by 365 · cited 1×
“In addition, the EMPROVE study, and other recent multicenter, randomized controlled trials, did not blind either subjects or assessors (16, 25, 34).”
Background
Research works printed but not linked: 3
- Elstad, 2012, Bronchial valve treatment of emphysema: procedure and device safety results from a double-blind randomized trial [abstract], Am J Respir Crit Care Med, 185, A1112
- Criner, 2018, The EMPROVE trial: a randomized, controlled multicenter clinical study to evaluate the safety and effectiveness of the Spiration® Valve System for single lobe treatment of severe emphysema [abstract], Am J Respir Crit Care Med, 197, A7753
- Criner, 2018, Endobronchial valves for severe emphysema: 12-month results of the EMPROVE trial, Eur Respir J, 52, OA4928
Cited by
Chronic obstructive pulmonary disease
Christenson, S. A., Smith, B. M., Bafadhel, M., & Putcha, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00470-6 · Cited by 1,219
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
“181-183 Survival benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the…”
BackgroundChronic Obstructive Pulmonary Disease
Labaki, W. W., & Rosenberg, S. R. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202008040 · Cited by 376
Advances in Chronic Obstructive Pulmonary Disease
Ferrera, M. C., Labaki, W. W., & Han, M. K. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-080919-112707 · Cited by 169
Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease
Easter, M., Bollenbecker, S., Barnes, J. W., & Krick, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186924 · Cited by 139
Metadata
- Authors
- Criner, G. J., Delage, A., Voelker, K., Hogarth, D. K., Majid, A., Zgoda, M., Lazarus, D. R., Casal, R., Benzaquen, S. B., Holladay, R. C., Wellikoff, A., Calero, K., Rumbak, M. J., Branca, P. R., Abu-Hijleh, M., Mallea, J. M., Kalhan, R., Sachdeva, A., Kinsey, C. M., Lamb, C. R., Reed, M. F., Abouzgheib, W. B., Kaplan, P. V., Marrujo, G. X., Johnstone, D. W., Gasparri, M. G., Meade, A. A., Hergott, C. A., Reddy, C., Mularski, R. A., Case, A. H., Makani, S. S., Shepherd, R. W., Chen, B., Holt, G. E., & Martel, S.
- Affiliations
- Temple University (US)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Sarasota Memorial Hospital (US)
- University of Chicago Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Carolinas Medical Center (US)
- Michael E. DeBakey VA Medical Center (US)
- University of Cincinnati (US)
- Louisiana State University Health Sciences Center Shreveport (US)
- University of South Florida (US)
- University of Tennessee Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- Mayo Clinic in Florida (US)
- Northwestern University (US)
- University of Maryland Medical Center (US)
- University of Vermont Medical Center (US)
- Lahey Hospital and Medical Center (US)
- Penn State Milton S. Hershey Medical Center (US)
- Cooper University Hospital (US)
- Botsford Hospital (US)
- Kaiser Permanente Riverside Medical Center (US)
- Froedtert Hospital (US)
- Sparks Regional Medical Center, Fort Smith, Arkansas
- University of Calgary (CA)
- University of Utah (US)
- Kaiser Permanente (US)
- Piedmont Atlanta Hospital (US)
- University of California San Diego (US)
- Virginia Commonwealth University (US)
- California Pacific Medical Center (US)
- Miami VA Healthcare System (US)
- Corresponding author
- Criner, Gerard J.
- ORCID
- Criner, Gerard J.
- Voelker, Kirk
- Hogarth, D. Kyle
- Majid, Adnan
- Lazarus, Donald R.
- Casal, Roberto
- Benzaquen, Sadia B.
- Calero, Karel
- Branca, Paul R.
- Abu-Hijleh, Muhanned
- Mallea, Jorge M.
- Kalhan, Ravi
- Sachdeva, Ashutosh
- Kinsey, C. Matthew
- Reed, Michael F.
- Abouzgheib, Wissam B.
- Hergott, Christopher A.
- Mularski, Richard A.
- Case, Amy Hajari
- Chen, Benson
- Holt, Gregory E.
- Martel, Simon
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-01
- Volume
- 200
- Issue
- 11
- Pages
- 1354-1362
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC6884033
- OpenAlex
- W2964927788
- Semantic Scholar
- 7f5d5df549b5139dae4c821801e8540d84cad2f9
- Cited by
- 182
- References
- 35
- Citations by year
- 2026: 20 · 2025: 29 · 2024: 30 · 2023: 24 · 2022: 20 · 2021: 28 · 2020: 26 · 2019: 5
- FWCI
- 14.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Spiration Inc. d.b.a. Olympus Respiratory America
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- heterogeneous emphysema, lung volume reduction, FEV1, lung function, pneumothorax, hyperinflation, dyspnea, exercise capacity, conservative treatment, chronic obstructive pulmonary disease
- MeSH terms
- Aged, Inhalation, Bronchi, Female, Forced Expiratory Volume, Humans, Lung, Male, Pulmonary Emphysema, Treatment Outcome, Prostheses and Implants
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. https://app.cochat.ai/papers/10.1164/rccm.201902-0383oc
- The paper
- Criner, G. J., Delage, A., Voelker, K., Hogarth, D. K., Majid, A., Zgoda, M., Lazarus, D. R., Casal, R., Benzaquen, S. B., Holladay, R. C., Wellikoff, A., Calero, K., Rumbak, M. J., Branca, P. R., Abu-Hijleh, M., Mallea, J. M., Kalhan, R., Sachdeva, A., Kinsey, C. M., . . . Martel, S. (2019). Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201902-0383oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.